ORIGINAL ARTICLE

Skin advanced glycation end products as biomarkers of photosensitivity in schizophrenia

Eriko Tani¹ | Tohru Ohnuma¹ | Hitoki Hirose¹ | Ken Nakayama¹ | Wanyi Mao¹ | Mariko Nakadaira¹ | Narihiro Orimo¹ | Hiroki Yamashita¹ | Yuto Takebayashi¹ | Yasue Miki¹ | Narimasa Katsuta¹ | Shohei Nishimon¹ | Toshio Hasegawa² | Etsuko Komiyama² | Yasushi Suga² | Shigaku Ikeda² | Heii Arai¹

¹Juntendo University Schizophrenia Projects (JUSP), Department of Psychiatry, Faculty of Medicine, Juntendo University, Tokyo, Japan

²Department of Dermatology and Allergology, Juntendo University Graduate School of Medicine, Tokyo, Japan

Correspondence

Tohru Ohnuma, Juntendo University Schizophrenia Projects (JUSP), Department of Psychiatry, Faculty of Medicine, Juntendo University, Tokyo, Japan.
Email: otoru@juntendo.ac.jp

Funding information

Juntendo Institute of Mental Health, Grant/Award Number: 201701

Abstract

Objectives: Photosensitivity to ultraviolet A (UVA) radiation from sunlight is an important side effect of treatment with antipsychotic agents. However, the pathophysiology of drug-induced photosensitivity remains unclear. Recent studies demonstrated the accumulation of advanced glycation end products (AGEs), annotated as carbonyl stress, to be associated with the pathophysiology of schizophrenia. In this study, we investigated the relationship among skin AGE levels, minimal response dose (MRD) with UVA for photosensitivity, and the daily dose of antipsychotic agents in patients with schizophrenia and healthy controls.

Methods: We enrolled 14 patients with schizophrenia and 14 healthy controls. Measurement of skin AGE levels was conducted with AGE scanner, a fluorometric method for assaying skin AGE levels. Measurement of MRD was conducted with UV irradiation device.

Results: Skin AGE levels and MRD at 24, 48, and 72 hr in patients with schizophrenia showed a higher tendency for photosensitivity than in the controls, but the difference was statistically insignificant. Multiple linear regression analysis using skin AGE levels failed to show any influence of independent variables. MRD did not affect skin AGE levels.

Conclusions: Photosensitivity to UVA in patients with schizophrenia receiving treatment with antipsychotic agents might not be affected by skin AGE levels.

KEYWORDS

advanced glycation end products, carbonyl stress, photosensitivity, schizophrenia

1 | INTRODUCTION

Researchers have long sought validated, reproducible, sensitive, and specific biomarkers of schizophrenia. Previous studies have demonstrated significant alterations in the levels of peripheral biomarkers, such as serum amino acids and inflammation markers levels of schizophrenia (Chan et al., 2015; Nishimon et al., 2017; Ohnuma et al., 2008; Ohnuma & Arai, 2011). Although the majority of previous studies

have demonstrated the potential of diagnostic or prognostic biomarkers, few cross-sectional observational studies have also examined the safety or toxicity of biomarkers for treatment with antipsychotic agents (Lai et al., 2016; Tomasik, Rahmoune, Guest, & Bahn, 2016). The accumulation of advanced glycation end products (AGEs) associated with glycation stress is known as carbonyl stress, and several recent studies have demonstrated an association between the pathophysiology of schizophrenia and carbonyl stress (Arai et al., 2010;

Katsuta et al., 2014; Kouidrat et al., 2013; Miyashita et al., 2013; Takeda et al., 2015). Previously, we reported that high serum levels of pentosidine, a marker of carbonyl stress, were associated with high doses of antipsychotic agents and the duration of polypharmacy treatment with antipsychotic agents in acute-stage schizophrenia (Katsuta et al., 2014; Sannohe et al., 2017). Other researchers demonstrated possible correlation between AGE levels and the duration of antipsychotic treatment as well as antipsychotic dose (Hagen et al., 2017). Serum pentosidine levels have not been associated with the severity of the symptoms of schizophrenia (Katsuta et al., 2014; Sannohe et al., 2017).

A photosensitive reaction, manifesting as a skin rash, is one of the side effects of antipsychotic drug-induced toxicity. Photosensitivity is believed to reflect a disturbed immune function after exposure of skin to sunlight and after the administration of not only typical antipsychotics, including phenothiazine (Wolnicka-Glubisz et al., 2005), but also current main stream of pharmacotherapy with atypical antipsychotics, including clozapine, aripiprazole, and aripiprazole (Al-Aojan & Al-Khalifah, 2018; Gregoriou et al., 2008). In addition, some cases transferred to persistent light reaction with cross-reaction mechanism, although the causal substance (antipsychotics) has been eliminated (Amblard, Beani, & Reymond, 1982; Barbaud et al., 2001). The main mechanism of photosensitivity was considered to be immunoreaction, especially delayed-type allergy. Photohaptens are the main causative substances in the first sensitisation of photosensitivity and bind covalently to protein under exposure to ultraviolet A (UVA) via Langerhans cells photomodified with a photohaptens, which can stimulate immune T cells; then these mechanisms were elicited by UVA irradiation (Tokura, 2000). Finally, these reactions cause skin inflammation that was also caused by accumulation of AGEs, which was caused by antipsychotics dose and considered as one of the pathophysiologic mechanisms of schizophrenia (Ohnuma et al., 2018). Thus, the accumulation of skin AGEs also might be involved in the pathophysiology underlying drug-induced photosensitivity. Indeed, the accumulation of AGEs in skin has been shown to be involved in the pathophysiology of some dermatological diseases, such as solar elastosis (Yoshinaga et al., 2012), prurigo nodularis in dialysis patients (Dyer et al., 1993; Meng et al., 2001), and perforating dermatosis (Fujimoto & Tajima, 2004; Seite et al., 1998).

In the current study, we investigated the relationship between photosensitivity and possible causative factors, including skin AGE levels, minimal response dose (MRD), daily antipsychotic doses, and

serum pentosidine and pyridoxal levels in patients with schizophrenia treated with antipsychotic agents and in healthy controls. We aimed to investigate whether a high glycated stress state is associated with overdose of antipsychotic drugs and the potential implication of using glycated stress as a biomarker of photosensitivity in schizophrenia.

2 | METHODS

2.1 | Subjects

The Ethics Committee of the Juntendo University School of Medicine approved the study protocol (15-052). All participants provided written informed consent prior to participation. Fourteen stable outpatients diagnosed with schizophrenia and treated with a fixed dose of antipsychotics for ≥ 30 days were enrolled in a cross-sectional observational study at Juntendo University Schizophrenia Project (Ohnuma et al., 2008). First-episode, drug-naïve patients were excluded from this study. All included patients met the *Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition*, criteria for schizophrenia (Association, 2013). Clinical symptoms were assessed using the Brief Psychiatric Rating Scale, with each item rated on a 7-point scale as previously described (Katsuta et al., 2014). Three patients treated with first-generation antipsychotics, 10 treated with second-generation antipsychotic, and one treated with both types of antipsychotics (polypharmacy) were enrolled. Total administered antipsychotics were converted to the chlorpromazine (CP) dose (Inada & Inagaki, 2015). In addition, 14 healthy controls without current or a history of psychosis according to the Japanese latest version of Structured Clinical Interview for *Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition*, were recruited through the website of the Juntendo Hospital. The inclusion criteria in this study were as follows: (a) age between 20 and 60 years to exclude ageing-related effects; (b) no photosensitivity caused by factors such as porphyria or xeroderma pigmentosum syndrome; (c) no polypharmacy, that is, no prescription history of >3 antipsychotic drugs; (d) no history of diabetes, atopic dermatitis, or kidney dysfunction; (e) no more than moderate obesity (i.e., body mass index [BMI] < 30 kg/m²); (f) no medication use resulting in hyperesthesia optica; and (g) no history of smoking or alcoholism. A schematic of the study protocol is presented in Figure 1.

FIGURE 1 Inclusion criteria and measurement of minimal response dose (MRD) to ultraviolet A

2.2 | Measurement of pentosidine

All blood samples were collected prior to breakfast to control for the influence of food and exercise. The samples were immediately centrifuged at room temperature for 5 min at 3,500 rpm ($2,400 \times g$), and the supernatant was frozen at -80°C until further use. The concentration of serum pentosidine was measured using a competitive enzyme-linked immunosorbent assay kit (FSK Pentosidine, FUSHIMI Pharmaceutical Co., Ltd., Kagawa, Japan), as previously described. Briefly, pronase was added to the serum to expose the protein-bound pentosidine molecules, and the samples were incubated at 55°C for 1.5 hr. After the stipulated reaction time, the mixtures were heated in boiling water for 15 min for enzyme inactivation. An antibody against pentosidine and the pretreated sample or a standard pentosidine solution were added to each well and incubated at 37°C for 1 hr. After washing, a peroxidase-labelled goat anti-rabbit immunoglobulin G polyclonal antibody was added and incubated at room temperature for 1 hr. Subsequently, a colour development reagent containing 3,3',5,5'-tetramethylbenzidine was added to each well. The reaction was stopped 10 min later by adding a 3,3',5,5'-tetramethylbenzidine stop buffer. Absorbance was measured within 10 min at 450 and 630 nm (main and reference wavelength, respectively; Katsuta et al., 2014).

2.3 | Measurement of pyridoxal

Serum pyridoxal levels were measured using high-performance liquid chromatography (HPLC) on a Hitachi L-7000 series (Hitachi, Ibaraki, Japan). Then 200- μl aliquots of the serum were added to 200- μl citrate buffer solution and 75- μl acid phosphatase followed by incubation at 37°C for 1 hr. After completion of hydrolysis, 300 μl of 20% trichloroacetic acid was added to the mixture followed by centrifugation for 10 min at 12,000 rpm ($12,000 \times g$) at 4°C . Subsequently, 400 μl of the upper aqueous layer was neutralised with 75- μl sodium acetate solution and used as HPLC reagent. The HPLC reagents were analysed with a Fluorescent Detector FP-2025 (Ex λ : 325 nm, Em λ : 395 nm; JASCO Corporation, Tokyo, Japan) and a Wakosil-II C_{18}HG (4.6 $\phi \times 250$ mm) column (Wako Pure Chemical Industries, Osaka, Japan). Detailed information regarding the HPLC conditions can be accessed in a previous study by Katsuta et al. (2014).

2.4 | Measurements of skin AGE levels

Measurement of skin AGE levels was conducted with a TruAge Scanner™ (Morinda Worldwide Inc.), which represents a fluorometric method for assaying AGE levels in the skin. The forearm of the patients' dominant arm was placed on the scanner. A prerequisite for this assay is that the skin in the area being measured must be healthy; homogeneous; free of birthmarks, tattoos, or excessive hair growth; and without recent exposure to skin creams or any substance possibly having fluorescent properties. All measurements lasted approximately 15 s and were performed in triplicate after which the results were presented as an average value (Hagen et al., 2017).

2.5 | Measurement of MRD

Measurement of MRD was conducted with UV irradiation device (UV109A, Herbert Waldmann GmbH & Co., KG). We conducted a "preliminary study" with some healthy volunteers; our preliminary data (unpublished) showed that MRD range of UVA in Japanese healthy controls were 15–30 J/cm² with present methods. In addition, the lowest MRD is known as 320 kJ/m² for UVA (360 nm), approximately 30 J/cm², and appearance of erythema at 24 to 72 hr with under 15-J/cm² UVA radiation means that these subjects assumed to have photosensitivity (Hawk, Young, & Ferguson, 2013). Thus, the maximum irradiation time was defined as 30 J/cm² in this study. Eight patch holes (0% = 30 J/cm², 20%, 30%, 40%, 50%, 60%, 70%, and 80%) were selected in a V strength rate cut-off filter. First, we irradiated the skin on the patients' front arm with UVA light. After 24, 48, and 72 hr, the exposed skin area was examined during a hospital visit (<http://www.jove.com/video/50175>; Heckman et al., 2013). Unfortunately, six patients who underwent MRD at 24 hr, one who underwent MRD at 48 hr, and two who underwent MRD at 72 hr were unable to visit the hospital owing to personal reasons. Thus, the number of patients who underwent MRD at 24, 48, and 72 hr was considered to be 8, 12, and 13, respectively.

2.6 | Statistical analysis

All statistical analyses were conducted using SPSS version 22 (IBM Corp., Armonk, NY). Chi-square tests were conducted to analyse the difference in terms of sex distribution between the groups. A *p* value < 0.05 was defined as the level of statistical significance. Differences in terms of serum pentosidine, pyridoxal and skin AGE levels, and MRD between the unpaired groups were examined using a two-tailed Mann-Whitney *U* test for comparison between the two groups (schizophrenia vs. healthy control). Correlation between the clinical features (e.g., age, BMI, and daily CP equivalent dose) and measured biomarkers was analysed using single correlation analysis (Spearman's correlation test).

Multiple linear regression analysis included factors that potentially contributed to significantly different skin AGE levels. These factors were selected on the basis of their significant correlation with reported altered clinical characteristics such as BMI, age, and daily CP equivalent dose and were set as independent variables. Finally, stepwise multiple regression analyses were performed for the potential significantly different skin AGE levels as dependent variables and for the three above-mentioned clinical variables as independent variables. The post hoc power analysis (1- β) was performed with G*Power (<http://www.gpower.hhu.de/>) with the condition $\alpha = 0.05$, effect size = 0.5, and each sample group size = 14.

3 | RESULTS

3.1 | Comparison of clinical variables

Clinical variables including the measured biomarker levels were compared between the patients and healthy controls (Table 1). Sex ratio,

TABLE 1 Comparison of clinical variables between the patients with schizophrenia and healthy controls

Variable	Patients with schizophrenia (n = 14)	Healthy control (n = 14)	Statistical test and p value	
			Mann–Whitney U test	
			t	p value
Sex, M/F	3/11	8/6	3.743 (χ^2)	0.120
Age, mean (year)	42.6 ± 10.7	35.7 ± 9.6	−1.819	0.069
BMI (kg/m ²)	22.9 ± 4.39	21.8 ± 3.24	−0.965	0.335
DOI (year)	18.1 ± 11.7	NA	NA	NA
Total BPRS scores	24.5 ± 3.1	NA	NA	NA
CP equivalent dose (mg/day)	333.9 ± 234.9	NA	NA	NA
Serum pyridoxal (ng/ml)	10.65 ± 6.52	27.58 ± 38.51	−2.112	0.035
Serum pentosidine (ng/ml)	48.27 ± 14.65	45.94 ± 14.69	−0.291	0.771
Skin AGEs (AU)	246.45 ± 65.17	211.69 ± 31.96	−1.817	0.108
MRD 24 hr (J/cm ²)	17.63 ± 8.40	13.93 ± 6.82	−0.997	0.319
MRD 48 hr (J/cm ²)	14.54 ± 6.46	14.36 ± 6.98	−0.222	0.825
MRD 72 hr (J/cm ²)	16.25 ± 6.45	14.79 ± 7.00	−0.316	0.752

Note. Variable data are presented as mean ± standard deviation and range. AGEs: advanced glycation end products; BMI: body mass index; BPRS: Brief Psychiatric Rating Scale; CP equivalent dose: chlorpromazine equivalent dose; DOI: duration of illness; MRD: minimal response dose.

age, and BMI as well as serum pentosidine did not differ between the groups (Table 1). However, the serum pyridoxal levels in the patients were significantly lower than in the healthy controls (Table 1). Although skin AGE levels in the patients with schizophrenia showed a higher tendency compared with the controls, they did not reach statistical significance. Furthermore, the MRD at 24, 48, and 72 hr showed higher tendencies in the patients with schizophrenia than in the controls, but the difference was also statistically insignificant. Post hoc power analysis for this statistic showed $(1-\beta) = 0.08$.

Single correlation analysis was performed among the carbonyl stress markers (serum pyridoxal and pentosidine and skin AGEs), MRD (24, 48, and 72 hr), and the three clinical variables (age, BMI, and daily CP equivalent dose) in patients with schizophrenia (Table S1). As expected, skin AGE levels showed a significant correlation with age ($r = 0.477$, $p = 0.010$) using single correlation analysis, but not with BMI ($r = 0.114$, $p = 0.562$) and daily CP equivalent dose (patients, $r = 0.018$, $p = 0.952$). Other carbonyl stress markers did not show significant correlation with any clinical variables (all $p > 0.05$). MRDs at 48 hr ($r = 0.386$, $p = 0.047$) and 72 hr ($r = 0.394$, $p = 0.047$) showed a marginally significant correlation with BMI. In the nature of things, three MRDs showed significant correlations with each other (Table S1). Post hoc power analysis for this statistic showed $(1-\beta) = 0.07$.

3.2 | Multiple linear regression analysis

Stepwise multiple linear regression analysis was performed in patients with schizophrenia using skin AGE levels as a dependent variable. Age, BMI, and CP equivalent dose showed a significant association with skin AGE levels in the present study (age) and previous studies (BMI and CP equivalent dose; Sannohe et al., 2017; Takeda et al., 2015) as independent variables. In this analysis, the three independent variables were excluded in the first stage of the analysis in predicting skin AGE levels. However, forced-entry multiple linear regression analysis was performed

using the same dependent and independent variables; however, no independent variables were shown to affect skin AGE levels ($F = 0.61$, $p = 0.62$). The stepwise multiple linear regression analysis was performed using MRD (24, 48, and 72 hr) as a dependent variable and age, BMI, CP equivalent dose, and skin AGE levels as independent variables. The results of these analyses showed that BMI was a significant variable for the prediction of MRD for 72 hr in the first stage of analysis ($F = 11.1$, $p = 0.009$), whereas age, CP equivalent dose, and skin AGE levels were not significant. The predictive equation for calculating MRD at 72 hr was as follows: $\text{MRD at 72 hr (J/cm}^2\text{)} = -6.6 + 0.98 \times \text{BMI}$. All independent variables were excluded in the first stage of the analysis for predicting skin AGE levels for MRD at 24 and 48 hr. Post hoc power analysis for this statistic showed $(1-\beta) = 0.06$.

4 | DISCUSSION

In the present study, we investigated the relation between photosensitivity using MRD and variable antipsychotic doses as the potential causative pathophysiological agents underlying the accumulation of skin AGEs. The results that higher tendency of serum pentosidine levels and significantly lower levels of serum pyridoxal in the patients with schizophrenia than in the healthy controls were consistent with and confirmed previous well-established results of studies that used serum biomarkers as indicators of carbonyl stress in schizophrenia (Arai et al., 2010; Katsuta et al., 2014; Kouidrat et al., 2013; Miyashita et al., 2013; Takeda et al., 2015). These results verified that the subjects enrolled in this study possibly presented features of carbonyl stress in a population suffering from schizophrenia. Although skin AGE levels in the patients with schizophrenia showed a higher tendency than in the healthy controls, they did not reach statistical significance. Measurement of skin AGE levels with the TruAge Scanner reflected on the levels of pentosidine, crossline (Obayashi et al., 1996), and pyrropyridine (Hayase et al., 2008) as those exerting fluorescence and cross-linkage

with collagen in the skin (Meerwaldt et al., 2005). Although apparent measured AGEs were not specifically restricted (Sell, Nemet, Liang, & Monnier, 2018), skin AGE levels showed a clear correlation with the concentration of skin pentosidine levels (Meerwaldt et al., 2005). The accumulation of skin AGEs related to risk for further complications in diseases such as cardiovascular disease and macular degenerative disease (Bos, de Ranitz-Greven, & de Valk, 2011; Lutgers et al., 2009) could prove useful as a surrogate marker of the status of carbonyl stress in the skin (Macasai, Takats, Derzbach, Korner, & Vasarhelyi, 2013). Thus, the status of carbonyl stress in patients with schizophrenia might vary depending on the affected tissues, for example, accumulation in the skin or peripheral blood.

The current study has certain limitations, such as the small number of subjects (14 patients with schizophrenia) with low statistical power (1- β ; from 0.06 to 0.08) compared with a previous large serum AGE level-driven study (274 patients with schizophrenia; Sannohe et al., 2017). Further, all patients of the present study were outpatients who showed milder symptoms and were prescribed lower daily doses antipsychotic agents compared with previous studies that included patients suffering with severe schizophrenia (Sannohe et al., 2017). Both factors, namely, mild disease symptoms and low dosing of antipsychotics, may affect the levels of peripheral carbonyl stress markers (Arai et al., 2010; Katsuta et al., 2014; Kouidrat et al., 2013; Miyashita et al., 2013; Takeda et al., 2015). Indeed, skin AGE levels were significantly elevated in patients with severe schizophrenia (Kouidrat et al., 2015). Furthermore, increased skin AGEs levels showed relation with antipsychotics dose and its accumulative exposure periods in patients with a recent onset of psychosis (Hagen et al., 2017), as we also showed in serum study (Sannohe et al., 2017).

Unfortunately, this study failed to demonstrate any significant association between daily antipsychotic drug dose and MRD with UVA on skin AGE levels. Further, a control for the specific type of antipsychotic drugs was not accounted for in this study. Among the 14 patients with schizophrenia, only one patient treated with polypharmacy showed the most influenced peripheral AGE levels (Sannohe et al., 2017). Although the results presented in this study are clinically relevant, they need to be reproduced in studies that include larger sample sizes and patients with severe schizophrenia treated with high doses of antipsychotic drugs. Patients treated with antipsychotic drugs showed a minor tendency to exhibit lower photosensitivity to UVA. Additionally, higher BMI might influence the MRD at 72 hr to show a higher value (i.e., lower photosensitivity to UVA) in patients with schizophrenia. Obesity has been suggested to trigger a higher status of carbonyl stress (Miyata, Yamamoto, & Izuhara, 2005; Nangaku et al., 2005). The current results demonstrated an inverse relation between BMI and MRD. Overall, we conclude that photosensitivity to UVA in patients with schizophrenia was not clinically apparent and was unaffected by skin AGE levels and related factors such as low antipsychotic drug dose.

Further studies using non-invasive measurement of skin AGE levels on a larger subject population, including those suffering from severe schizophrenia and especially those with demonstrated history of photosensitive reaction to antipsychotic agents, might be beneficial in clinical practice for the treatment of schizophrenia.

DECLARATION OF INTEREST STATEMENT

None to declare.

ACKNOWLEDGEMENTS

This work was financially supported by the Juntendo Institute of Mental Health 2017 (201701). This funding source had no further role in study design, data collection, analysis, and manuscript writing. The authors would like to thank Enago (www.enago.jp) for English language review.

AUTHOR CONTRIBUTIONS

Eriko Tani and Tohru Ohnuma designed the study protocol, recruited subjects, collected clinical data, performed statistical analysis, and wrote the manuscript. Yuto Takebayashi, Narimasa Katsuta, and Shohei Nishimon designed the study, recruited subjects, and collected clinical data. Hitoki Hirose, Ken Nakayama, Wanyi Mao, Mariko Nakadaira, Narihiro Orimo, Hiroki Yamashita, and Yasue Miki assisted in manuscript preparation. Toshio Hasegawa, Etsuko Komiyama, Yasushi Suga, and Shigaku Ikeda contributed to study design and interpretation of analysed dermatological data. Heii Arai contributed to the interpretation of all analysed data. All authors contributed to manuscript preparation and approved the final version.

ORCID

Tohru Ohnuma <https://orcid.org/0000-0003-1522-3832>

REFERENCES

- Al-Aojan, S., & Al-Khalifah, A. (2018). Clozapine-induced phototoxicity: An unusual side effect of atypical antipsychotics. *Case Reports in Dermatological Medicine*, 2018, 1–2. <https://doi.org/10.1155/2018/9242515>
- Amblard, P., Beani, J. C., & Reymond, J. L. (1982). Persistent light reaction due to phenothiazines in atopic disease (author's transl). *Annales de Dermatologie et de Vénérologie*, 109(3), 225–228.
- Arai, M., Yuzawa, H., Nohara, I., Ohnishi, T., Obata, N., Iwayama, Y., ... Itokawa, M. (2010). Enhanced carbonyl stress in a subpopulation of schizophrenia. *Archives of General Psychiatry*, 67(6), 589–597. <https://doi.org/10.1001/archgenpsychiatry.2010.62>
- Association AP (2013). *Diagnostic and statistical manual of mental disorders* (5th ed.) American Psychiatric Association. <https://doi.org/10.1176/appi.books.9780890425596>
- Barbaud, A., Collet, E., Martin, S., Granel, F., Trechot, P., Lambert, D., & Schmutz, J. L. (2001). Contact sensitization to chlorproethazine can induce persistent light reaction and cross-photoreactions to other phenothiazines. *Contact Dermatitis*, 44(6), 373.
- Bos, D. C., de Ranitz-Greven, W. L., & de Valk, H. W. (2011). Advanced glycation end products, measured as skin autofluorescence and diabetes complications: A systematic review. *Diabetes Technology & Therapeutics*, 13(7), 773–779. <https://doi.org/10.1089/dia.2011.0034>
- Chan, M. K., Krebs, M. O., Cox, D., Guest, P. C., Yolken, R. H., Rahmoune, H., ... Bahn, S. (2015). Development of a blood-based molecular biomarker test for identification of schizophrenia before disease onset. *Translational Psychiatry*, 5, e601. <https://doi.org/10.1038/tp.2015.91>
- Dyer, D. G., Dunn, J. A., Thorpe, S. R., Bailie, K. E., Lyons, T. J., McCance, D. R., & Baynes, J. W. (1993). Accumulation of Maillard reaction products in skin collagen in diabetes and aging. *The Journal of Clinical Investigation*, 91(6), 2463–2469. <https://doi.org/10.1172/jci116481>
- Fujimoto, N., & Tajima, S. (2004). Advanced glycation end product (AGE)-immunoreactive materials in chronic prurigo patients receiving a long-

- standing haemodialysis. *The British Journal of Dermatology*, 150(4), 757–760. <https://doi.org/10.1111/j.0007-0963.2004.05864.x>
- Gregoriou, S., Karagiorga, T., Stratigos, A., Volonakis, K., Kontochristopoulos, G., & Rigopoulos, D. (2008). Photo-onycholysis caused by olanzapine and aripiprazole. *Journal of Clinical Psychopharmacology*, 28(2), 219–220. <https://doi.org/10.1097/JCP.0b013e318166c50a>
- Hagen, J. M., Sutherland, A. L., Koeter, M. W., Lutter, R., Cohen, D., & de Haan, L. (2017). Advanced glycation end products in recent-onset psychosis indicate early onset of cardiovascular risk. *The Journal of Clinical Psychiatry*, 78(9), 1395–1401. <https://doi.org/10.4088/JCP.16m10972>
- Hawk, J. L. M., Young, A. R., & Ferguson, J. (2013). Rook's textbook of dermatology. In B. Tony, B. Stephen, C. Neil, & G. Christopher (Eds.), 29.5 *Normal cutaneous effects of UVR exposure*. UK: WILEY-BLACKWELL.
- Hayase, F., Usui, T., Ono, Y., Shirahashi, Y., Machida, T., Ito, T., ... Watanabe, H. (2008). Formation mechanisms of melanoidins and fluorescent pyridinium compounds as advanced glycation end products. *Annals of the New York Academy of Sciences*, 1126, 53–58. <https://doi.org/10.1196/annals.1433.009>
- Heckman, C. J., Chandler, R., Kloss, J. D., Benson, A., Rooney, D., Munshi, T., ... Oslin, D. W. (2013). Minimal erythema dose (MED) testing. *Journal of Visualized Experiments: JoVE*, 75, e50175. <https://doi.org/10.3791/50175>
- Inada, T., & Inagaki, A. (2015). Psychotropic dose equivalence in Japan. *Psychiatry and Clinical Neurosciences*, 69(8), 440–447. <https://doi.org/10.1111/pcn.12275>
- Katsuta, N., Ohnuma, T., Maeshima, H., Takebayashi, Y., Higa, M., Takeda, M., ... Arai, H. (2014). Significance of measurements of peripheral carbonyl stress markers in a cross-sectional and longitudinal study in patients with acute-stage schizophrenia. *Schizophrenia Bulletin*, 40(6), 1366–1373. <https://doi.org/10.1093/schbul/sbt234>
- Kouidrat, Y., Amad, A., Arai, M., Miyashita, M., Lalau, J. D., Loas, G., & Itokawa, M. (2015). Advanced glycation end products and schizophrenia: A systematic review. *Journal of Psychiatric Research*, 66–67, 112–117. <https://doi.org/10.1016/j.jpsychires.2015.04.023>
- Kouidrat, Y., Amad, A., Desaillood, R., Diouf, M., Fertout, E., Scoury, D., ... Loas, G. (2013). Increased advanced glycation end-products (AGEs) assessed by skin autofluorescence in schizophrenia. *Journal of Psychiatric Research*, 47(8), 1044–1048. <https://doi.org/10.1016/j.jpsychires.2013.03.016>
- Lai, C. Y., Scarr, E., Udawela, M., Everall, I., Chen, W. J., & Dean, B. (2016). Biomarkers in schizophrenia: A focus on blood based diagnostics and theranostics. *World Journal of Psychiatry*, 6(1), 102–117. <https://doi.org/10.5498/wjpv.v6.i1.102>
- Lutgers, H. L., Gerrits, E. G., Graaff, R., Links, T. P., Sluiter, W. J., Gans, R. O., ... Smit, A. J. (2009). Skin autofluorescence provides additional information to the UK Prospective Diabetes Study (UKPDS) risk score for the estimation of cardiovascular prognosis in type 2 diabetes mellitus. *Diabetologia*, 52(5), 789–797. <https://doi.org/10.1007/s00125-009-1308-9>
- Macasai, E., Takats, Z., Derzbach, L., Korner, A., & Vasarhelyi, B. (2013). Verification of skin autofluorescence values by mass spectrometry in adolescents with type 1 diabetes: Brief report. *Diabetes Technology & Therapeutics*, 15(3), 269–272. <https://doi.org/10.1089/dia.2012.0251>
- Meerwaldt, R., Links, T., Graaff, R., Thorpe, S. R., Baynes, J. W., Hartog, J., ... Smit, A. (2005). Simple noninvasive measurement of skin autofluorescence. *Annals of the New York Academy of Sciences*, 1043, 290–298. <https://doi.org/10.1196/annals.1333.036>
- Meng, J., Sakata, N., Imanaga, Y., Takebayashi, S., Nagai, R., & Horiuchi, S. (2001). Carboxymethyllysine in dermal tissues of diabetic and nondiabetic patients with chronic renal failure: Relevance to glycoxidation damage. *Nephron*, 88(1), 30–35. <https://doi.org/10.1159/000045955>
- Miyashita, M., Arai, M., Kobori, A., Ichikawa, T., Toriumi, K., Niizato, K., ... Itokawa, M. (2013). Clinical features of schizophrenia with enhanced carbonyl stress. *Schizophrenia Bulletin*, 40, 1040–1046. <https://doi.org/10.1093/schbul/sbt129>
- Miyata, T., Yamamoto, M., & Izuhara, Y. (2005). From molecular footprints of disease to new therapeutic interventions in diabetic nephropathy. *Annals of the New York Academy of Sciences*, 1043, 740–749. <https://doi.org/10.1196/annals.1333.086>
- Nangaku, M., Izuhara, Y., Usuda, N., Inagi, R., Shibata, T., Sugiyama, S., ... Miyata, T. (2005). In a type 2 diabetic nephropathy rat model, the improvement of obesity by a low calorie diet reduces oxidative/carbonyl stress and prevents diabetic nephropathy. *Nephrology Dialysis Transplantation*, 20(12), 2661–2669. <https://doi.org/10.1093/ndt/gfi096>
- Nishimon, S., Ohnuma, T., Takebayashi, Y., Katsuta, N., Takeda, M., Nakamura, T., ... Arai, H. (2017). High serum soluble tumor necrosis factor receptor 1 predicts poor treatment response in acute-stage schizophrenia. *Progress in Neuro-Psychopharmacology & Biological Psychiatry*, 76, 145–154. <https://doi.org/10.1016/j.pnpbp.2017.03.006>
- Obayashi, H., Nakano, K., Shigeta, H., Yamaguchi, M., Yoshimori, K., Fukui, M., ... Kondo, M. (1996). Formation of crossline as a fluorescent advanced glycation end product in vitro and in vivo. *Biochemical and Biophysical Research Communications*, 226(1), 37–41. <https://doi.org/10.1006/bbrc.1996.1308>
- Ohnuma, T., & Arai, H. (2011). Significance of NMDA receptor-related glutamatergic amino acid levels in peripheral blood of patients with schizophrenia. *Progress in Neuro-Psychopharmacology & Biological Psychiatry*, 35(1), 29–39. <https://doi.org/10.1016/j.pnpbp.2010.08.027>
- Ohnuma, T., Nishimon, S., Takeda, M., Sannohe, T., Katsuta, N., & Arai, H. (2018). Carbonyl stress and microinflammation-related molecules as potential biomarkers in schizophrenia. *Frontiers in Psychiatry*, 9, 82. <https://doi.org/10.3389/fpsy.2018.00082>
- Ohnuma, T., Sakai, Y., Maeshima, H., Hatano, T., Hanzawa, R., Abe, S., ... Arai, H. (2008). Changes in plasma glycine, l-serine, and d-serine levels in patients with schizophrenia as their clinical symptoms improve: Results from the Juntendo University Schizophrenia Projects (JUSP). *Progress in Neuro-Psychopharmacology & Biological Psychiatry*, 32(8), 1905–1912. <https://doi.org/10.1016/j.pnpbp.2008.07.022>
- Sannohe, T., Ohnuma, T., Takeuchi, M., Tani, E., Miki, Y., Takeda, M., ... Arai, H. (2017). High doses of antipsychotic polypharmacy are related to an increase in serum levels of pentosidine in patients with schizophrenia. *Progress in Neuro-Psychopharmacology & Biological Psychiatry*, 76, 42–48. <https://doi.org/10.1016/j.pnpbp.2017.02.019>
- Seite, S., Moyal, D., Richard, S., de Rigal, J., Leveque, J. L., Hourseau, C., & Fourtanier, A. (1998). Mexoryl SX: A broad absorption UVA filter protects human skin from the effects of repeated suberythemal doses of UVA. *Journal of Photochemistry and Photobiology B, Biology*, 44(1), 69–76. [https://doi.org/10.1016/S1011-1344\(98\)00122-5](https://doi.org/10.1016/S1011-1344(98)00122-5)
- Sell, D. R., Nemet, I., Liang, Z., & Monnier, V. M. (2018). Evidence of glucuronidation of the glycation product LW-1: Tentative structure and implications for the long-term complications of diabetes. *Glycoconjugate Journal*, 35(2), 177–190. <https://doi.org/10.1007/s10719-017-9810-7>
- Takeda, M., Ohnuma, T., Takeuchi, M., Katsuta, N., Maeshima, H., Takebayashi, Y., ... Arai, H. (2015). Altered serum glyceraldehyde-derived advanced glycation end product (AGE) and soluble AGE receptor levels indicate carbonyl stress in patients with schizophrenia. *Neuroscience Letters*, 593, 51–55. <https://doi.org/10.1016/j.neulet.2015.03.002>
- Tokura, Y. (2000). Immune responses to photohaptens: Implications for the mechanisms of photosensitivity to exogenous agents. *Journal of Dermatological Science*, 23(Suppl 1), S6–S9. [https://doi.org/10.1016/S0923-1811\(99\)00071-7](https://doi.org/10.1016/S0923-1811(99)00071-7)
- Tomasik, J., Rahmoune, H., Guest, P. C., & Bahn, S. (2016). Neuroimmune biomarkers in schizophrenia. *Schizophrenia Research*, 176(1), 3–13. <https://doi.org/10.1016/j.schres.2014.07.025>
- Wolnicka-Glubisz, A., Rajwa, B., Dobrucki, J., Skrzeczynska-Moncznik, J., van Henegouwen, G. B., & Sarna, T. (2005). Phototoxicity, distribution and kinetics of association of UVA-activated chlorpromazine, 8-methoxypsoralen, and 4,6,4'-trimethylangelicin in Jurkat cells. *Journal of Photochemistry and Photobiology B, Biology*, 78(2), 155–164. <https://doi.org/10.1016/j.jphotobiol.2004.11.002>

Yoshinaga, E., Kawada, A., Ono, K., Fujimoto, E., Wachi, H., Harumiya, S., ... Tajima, S. (2012). N ϵ -(Carboxymethyl)lysine modification of elastin alters its biological properties: Implications for the accumulation of abnormal elastic fibers in actinic elastosis. *The Journal of Investigative Dermatology*, 132(2), 315–323. <https://doi.org/10.1038/jid.2011.298>

SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section at the end of the article.

How to cite this article: Tani E, Ohnuma T, Hirose H, et al. Skin advanced glycation end products as biomarkers of photosensitivity in schizophrenia. *Int J Methods Psychiatr Res*. 2019;28:e1769. <https://doi.org/10.1002/mpr.1769>